Oragenics Achieves Revolutionary Breakthrough in Battling MRSA and VRE!

Oragenics Inc. (NYSE American: OGEN) is thrilled to announce the successful results of its lantibiotics platform in combating multiple resistant pathogens. This novel class of antibiotics has the potential to treat serious, life-threatening infections, and the laboratory testing has proven that it is capable of doing so. This development is a major step forward in the fight against infectious diseases.

Oragenics is pioneering a new approach to antibiotic development through its lantibiotics platform, which seeks to create effective treatments for deadly pathogens such as vancomycin-resistant Enterococci (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). Through its partnership with Linnaeus Bioscience Inc., Oragenics is now conducting preclinical testing to bring these new antibiotics to market.

Linnaeus Bioscience testing revealed that certain lantibiotic structures developed by Oragenics had the capacity to combat even the most resistant strains of MRSA and VRE, including clinical isolates that were resistant to oxacillin, methicillin, vancomycin and daptomycin – the last-resort drugs of choice.

Oragenics is proud to announce that its recent collaboration with Linnaeus has verified that its novel class of antibiotics is effective against even the most resistant of pathogens, including vancomycin and daptomycin. This marks a major milestone in the company’s mission to develop novel therapies to fight infectious diseases. President and Chief Executive Officer Murphy commented, “We are encouraged by the outcomes of our collaboration, which demonstrates that life-threatening pathogens remain sensitive to our lantibiotic compounds. This is an important step forward in our efforts to identify a new lead compound to advance into the clinic.”

Dr. Marc Sharp, Chief Scientific Officer of Linnaeus Bioscience and an acclaimed expert on antibiotic mechanism of action, recently declared that antimicrobial resistance is an ever-growing and concerning issue in the clinical world. Through a partnership with Oragenics, he and his team proved that even with multidrug-resistance phenotypes, clinically-relevant samples and contemporary clinical isolates are still sensitive to common lantibiotics, such as vancomycin and daptomycin, which are often prescribed to treat severe healthcare-associated MRSA infections.

More than 2.8 million cases of antibiotic-resistant infections and 35,000 fatalities occur in the United States each year. In response, Oragenics is dedicated to tackling this life-threatening health crisis by harnessing its novel lantibiotics platform. Through its collaboration with Linnaeus Bioscience, the company is making progress toward its ultimate aim of providing safe and effective solutions to infectious diseases, such as MRSA and VRE. Oragenics is steadfast in its mission to combat infectious diseases and save lives.

About Linnaeus Bioscience Inc.

At Linnaeus Bioscience Inc., our mission is to revolutionize drug discovery and accelerate the development of new antibiotics. Our proprietary Bacterial Cytological Profiling (BCP) platform was developed at the University of California San Diego and provides a powerful tool to uncover the mechanisms of action of antibiotics. We use this cutting-edge technology to develop our own pipeline of molecules that target Gram-negative bacteria and offer BCP on a fee-for-service basis. Established in 2012, we strive to make a lasting impact on the fight against superbugs.

About Oragenics, Inc.

Oragenics, Inc. is a development-stage company on a mission to fight against diseases caused by coronaviruses and other multidrug-resistant organisms. As a leading product, NT-CoV2-1 is an intranasal vaccine candidate that seeks to prevent COVID-19 and its variants. This innovative program uses licensed spike protein research from the NIH and NRC, with the goal to reduce viral transmission and provide a more convenient intranasal administration. Additionally, the company is also creating a novel class of antibiotics to tackle bacteria that have become resistant to existing commercial antibiotics.

Leave a Comment